Performance analysis of CytoMed Therapeutics (GDTC)
Annual Return
Over the past 3 years, GDTC has had an average annual return of -36.56%, underperforming the benchmark SPY, which returned +19.63% annual.
Since Apr 14, 2023, GDTC has had an average annual return of -35.36%, underperforming the benchmark SPY, which returned +21.49% annual.
| 2026 | 2025 | 2024 | 2023 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.10% | -60.73% | -30.61% | +22.50% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -39.57% | +33.86% | -7.41% | -0.28% | +17.33% | -11.97% | -6.80% | -28.10% | |||||
| 2025 | -22.35% | +6.06% | -22.13% | +8.70% | -2.11% | -3.02% | -16.44% | +6.49% | -0.60% | +10.55% | -16.36% | -27.43% | -60.73% |
| 2024 | -27.76% | -43.22% | +7.96% | -2.76% | +2.37% | -3.70% | -12.98% | -18.17% | +6% | +53.50% | -2.49% | +44.68% | -30.61% |
| 2023 | -16.25% | -18.51% | +11.72% | +42.62% | -22.40% | +3.69% | +6.57% | -1.07% | +32.79% | +22.50% |
Drawdown analysis of CytoMed Therapeutics (GDTC)
The maximum drawdown for the GDTC was -87.18%, occurring on May 7, 2026. This drawdown has not yet recovered.
The current GDTC drawdown is -82.98%.
Since Apr 14, 2023 GDTC has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 3 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -87.18% | Jul 11, 2023 | 709 | May 7, 2026 | Ongoing | Ongoing | Ongoing |
| -39.23% | May 8, 2023 | 14 | May 26, 2023 | 29 | Jul 11, 2023 | 43 |
| -18.75% | Apr 14, 2023 | 7 | Apr 25, 2023 | 9 | May 8, 2023 | 16 |